These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 7549041

  • 1. A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.
    Hashimoto S, Danks MK, Chatterjee S, Beck WT, Berger NA.
    Oncol Res; 1995; 7(1):21-9. PubMed ID: 7549041
    [Abstract] [Full Text] [Related]

  • 2. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
    Hashimoto S, Chatterjee S, Ranjit GB, Bao C, Ford J, Ganapathi R, Berger SJ, Berger NA.
    Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
    Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, Harker WG, Zwelling LA, Futscher BW, Suttle DP, Beck WT.
    Cancer Res; 1993 Mar 15; 53(6):1373-9. PubMed ID: 8383009
    [Abstract] [Full Text] [Related]

  • 5. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T, René B, Le Mée S, Lambert B, Saucier JM, Markovits J, Jacquemin-Sablon H, Jacquemin-Sablon A.
    Cancer Res; 1999 Oct 01; 59(19):4927-36. PubMed ID: 10519406
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, Sehested M.
    Cancer Res; 1999 Jul 15; 59(14):3442-50. PubMed ID: 10416608
    [Abstract] [Full Text] [Related]

  • 8. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES.
    Oncol Res; 1996 Jul 15; 8(3):101-10. PubMed ID: 8823806
    [Abstract] [Full Text] [Related]

  • 9. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
    Hirota H, Gosky D, Berger NA, Chatterjee S.
    Int J Oncol; 2002 Feb 15; 20(2):311-8. PubMed ID: 11788894
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
    Kubo T, Kohno K, Ohga T, Taniguchi K, Kawanami K, Wada M, Kuwano M.
    Cancer Res; 1995 Sep 01; 55(17):3860-4. PubMed ID: 7641205
    [Abstract] [Full Text] [Related]

  • 12. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone.
    Harker WG, Slade DL, Parr RL, Holguin MH.
    Cancer Res; 1995 Nov 01; 55(21):4962-71. PubMed ID: 7585537
    [Abstract] [Full Text] [Related]

  • 13. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
    Oloumi A, MacPhail SH, Johnston PJ, Banáth JP, Olive PL.
    Cancer Res; 2000 Oct 15; 60(20):5747-53. PubMed ID: 11059769
    [Abstract] [Full Text] [Related]

  • 14. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
    Takano H, Ise T, Nomoto M, Kato K, Murakami T, Ohmori H, Imamura T, Nagatani G, Okamoto T, Ohta R, Furukawa M, Shibao K, Izumi H, Kuwano M, Kohno K.
    Anticancer Drug Des; 1999 Apr 15; 14(2):87-92. PubMed ID: 10405635
    [Abstract] [Full Text] [Related]

  • 15. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
    Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H, Liu LF.
    Biochemistry; 1999 Aug 17; 38(33):10793-800. PubMed ID: 10451375
    [Abstract] [Full Text] [Related]

  • 16. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M, Beck WT.
    Oncol Res; 1995 Aug 17; 7(2):103-11. PubMed ID: 7579726
    [Abstract] [Full Text] [Related]

  • 17. Cell fusion studies to examine the mechanism for etoposide resistance in Chinese hamster V79 spheroids.
    Luo C, Johnston PJ, MacPhail SH, Banáth JP, Oloumi A, Olive PL.
    Exp Cell Res; 1998 Sep 15; 243(2):282-9. PubMed ID: 9743588
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
    Nitiss JL, Vilalta PM, Wu H, McMahon J.
    Mol Pharmacol; 1994 Oct 15; 46(4):773-7. PubMed ID: 7969059
    [Abstract] [Full Text] [Related]

  • 20. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH.
    Cancer Res; 1994 Jan 01; 54(1):152-8. PubMed ID: 7903202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.